Published in Clin Pharmacol Ther on September 13, 1972
Laxative abuse. Gut (1974) 1.54
Letter: Hazards of multilaxative mixtures. Br Med J (1976) 0.75
The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med (1993) 4.61
Drug treatment of dyslipidemias: practical guidelines for the primary care physician. Heart Dis Stroke (1994) 2.68
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol (1997) 1.98
Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. N Engl J Med (1967) 1.97
Reaction between S-nitrosothiols and thiols: generation of nitroxyl (HNO) and subsequent chemistry. Biochemistry (1998) 1.83
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther (2001) 1.65
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol (1998) 1.56
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med (1994) 1.46
The meetabolism of amiloride hydroloride in man. Clin Pharmacol Ther (1969) 1.33
The effect of spironolactone on antipyrine metabolism in man. Pharmacology (1973) 1.31
Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man. Biochem Pharmacol (1974) 1.28
Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract (2003) 1.19
Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci U S A (2000) 1.14
Absorption and metabolism of L-dopa by the human stomach. Eur J Clin Invest (1971) 1.07
Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am (1973) 1.06
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology (1972) 1.00
Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther (1978) 0.99
Differences in P-450 cytochromes from livers of rats treated with phenobarbital and with 3-methylcholanthrene. J Biol Chem (1973) 0.99
L-dopa treatment failure: explanation and correction. Br Med J (1970) 0.95
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol (1994) 0.92
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Induction of drug metabolism. 3. Further information of a new P-450 hemoprotein after treatment of rats with 3-methylcholanthrene. Mol Pharmacol (1969) 0.91
Long-term blood cholesterol-lowering effects of a dietary fiber supplement. Am J Prev Med (1999) 0.89
Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. Am J Med (1991) 0.88
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med (1987) 0.88
Acute toxicity of benzene inhalation to hemopoietic precursor cells. Toxicol Appl Pharmacol (1977) 0.87
Absorption and excretion of clindamycin-2-phosphate in children after intramuscular injection. Clin Pharmacol Ther (1972) 0.86
The instability of isoniazid and acetylisoniazid in frozen plasma. Res Commun Chem Pathol Pharmacol (1976) 0.86
Digoxin therapy during T-tube biliary drainage in man. JAMA (1978) 0.86
Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism (1993) 0.85
Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology (1975) 0.85
Drug interactions with fibric acids. Pharmacol Ther (1994) 0.85
L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro. Biochem Pharmacol (1971) 0.83
Diphenylhydantoin potency and plasma protein binding. J Pharmacol Exp Ther (1975) 0.83
Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. J Am Coll Nutr (1991) 0.83
Enterohepatic circulation of sulindac and metabolites. Clin Pharmacol Ther (1983) 0.83
N-hydroxybenzenecarboximidic acid derivatives: a new class of nitroxyl-generating prodrugs. Nitric Oxide (2001) 0.83
Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis (1986) 0.83
Cholestyramine and spironolactone and their combination in digitoxin elimination. Clin Pharmacol Ther (1980) 0.82
Quantitation of biliary excretion of drugs in man. Clin Pharmacol Ther (1982) 0.82
Drug interactions of lipid-altering drugs. Drug Saf (1998) 0.82
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis (2000) 0.82
Methods to assess relative reliability of diet records: minimum records for monitoring lipid and caloric intake. J Am Diet Assoc (1986) 0.81
Diabetes increases excretion of urinary malonaldehyde conjugates in rats. Lipids (1993) 0.81
Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr (1975) 0.81
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol (2000) 0.81
Dual hepatic metabolism of cerivastatin--clarifications. Am J Cardiol (1999) 0.81
Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects. Atherosclerosis (1988) 0.80
Biliary excretion of lead in rats, rabbits, and dogs. Toxicol Appl Pharmacol (1974) 0.80
Cytochrome P-420: tubular aggregated from hepatic microsomes. Science (1969) 0.80
A two-year crossover therapeutic trial with halofenate and clofibrate. Am J Med Sci (1977) 0.80
Effects of a low saturated fat, low cholesterol fish oil supplement in hypertriglyceridemic patients. A placebo-controlled trial. Ann Intern Med (1988) 0.80
The interaction between halofenate and propranolol. Clin Pharmacol Ther (1976) 0.80
Low- vs high-dose aspirin. Effects on platelet function in hyperlipoproteinemic and normal subjects. Arch Intern Med (1986) 0.80
Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans. Clin Pharmacol Ther (1990) 0.80
Hepatotoxicity of phenothiazines in vitro as measured by loss of aminotransferases to surrounding media. Proc Soc Exp Biol Med (1968) 0.79
Inhibiting cholesterol absorption with CP-88,818 (beta-tigogenin cellobioside; tiqueside): studies in normal and hyperlipidemic subjects. J Cardiovasc Pharmacol (1997) 0.79
A clinical pharmacologist's view of drug hepatotoxicity. Pharmacol Res Commun (1977) 0.79
Serum lipids in normo- and hyperlipidemics after methyldopa and propranolol. Clin Pharmacol Ther (1984) 0.79
Serum digitoxin in uremic patients. Clin Pharmacol Ther (1972) 0.79
Urinary response to in vivo lipid peroxidation induced by vitamin E deficiency. Lipids (1992) 0.79
Experimental bases for the different hepatotoxicity of erythromycin preparations in man. J Lab Clin Med (1972) 0.79
Probucol. Curr Atheroscler Rep (2000) 0.78
The alteration of plasma proteins in uremia as reflected in the ability to bind diphenylhydantoin. Ann N Y Acad Sci (1973) 0.78
Comparative clinical therapeutic trial with two hypolipidemic drugs: lofibrate and nafenopin. Clin Pharmacol Ther (1971) 0.78
Arachidonic and docosahexanoic acid content of bovine brain myelin: implications for the pathogenesis of multiple sclerosis. Neurochem Res (1990) 0.78
The correlation of serum levels of two transaminases with tissue levels in six vertebrate species. Comp Biochem Physiol (1968) 0.78
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis (2001) 0.78
Liver cell culture toxicity and surfactant potency of erythromycin derivatives. Toxicol Appl Pharmacol (1975) 0.78
Hepatotoxic and cellular uptake interactions among surface active components of erythromycin preparations. Biochem Pharmacol (1978) 0.78
The combined effects of N-3 fatty acids and aspirin on hemostatic parameters in man. Thromb Res (1990) 0.77
Chlorpromazine uptake by isolated rat hepatocytes. Proc Soc Exp Biol Med (1979) 0.77
Protection of superoxide-induced cholesterol oxidation by antioxidants in protic conditions. Int J Food Sci Nutr (2002) 0.77
The effect of superoxide anion in the production of seven major cholesterol oxidation products in aptoric and protic conditions. Int J Food Sci Nutr (1997) 0.77
Inhibition of amphetamine tolerance and metabolism by propranolol. J Pharmacol Exp Ther (1974) 0.77
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol (1995) 0.77
Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia. Clin Cardiol (2001) 0.76
One-year trials with halofenate, clofibrate, and placebo. Clin Pharmacol Ther (1976) 0.76
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis (1995) 0.76
Cytotoxicity of phenothiazines on Chang liver cells as measured by enzyme leakage. Proc Soc Exp Biol Med (1969) 0.76
Omega-3 fatty acids in hypertriglyceridemic patients: triglycerides vs methyl esters. Am J Clin Nutr (1988) 0.76
Toxicity of promazine and chlorpromazine to isolated rat hepatocytes and its modification by liposome entrapment. Pharmacology (1986) 0.75
Evidence that inhibition of hepatic drug oxidation by tumors is mediated by a circulating humor. Proc Soc Exp Biol Med (1972) 0.75
The high risk cardiovascular patient. Kans Med (1985) 0.75
Alterations of liver-cell membranes after exposure to halothane. N Engl J Med (1980) 0.75
Erythromycin estolate vs. erythromycin base, surface excess properties and surface scanning changes in isolated liver cell systems. Pharmacology (1980) 0.75
Electrocardiographic effects of probucol. A controlled prospective clinical trial. Eur J Clin Pharmacol (1984) 0.75
Placental transfer of diphenylhydantoin in the goat. Biochem Pharmacol (1972) 0.75
Drug treatment of hyperlipidemia. Ration Drug Ther (1984) 0.75
Ethical, medical and legal issues for the use of placebos in future lipid intervention trials. Curr Opin Lipidol (2001) 0.75
Prevention of toxicity to isolated hepatocytes by liposome entrapment of chenodeoxycholic acid. Toxicol Lett (1984) 0.75
Lipid-altering drugs in development. Drugs R D (1999) 0.75
Controlled studies of the efficacy and safety of combined probucol-colestipol therapy. Am J Cardiol (1986) 0.75
Platelet function in hypercholesterolemics before and after hypolipidemic drug therapy. Haemostasis (1986) 0.75
Probucol with colestipol in the treatment of hypercholesterolemia. Ann Intern Med (1984) 0.75
Low-dose colestipol plus probucol for hypercholesterolemia. Am J Cardiol (1984) 0.75
The effect of variable fat diets and cholesterol-lowering drugs on Antithrombin III levels in hyperlipoproteinemic and normal subjects. Thromb Res (1983) 0.75